NASDAQ:INSMInsmed Stock Price, Forecast & News

Insmed's stock was trading at $21.25 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INSM stock has increased by 31.6% and is now trading at $27.97. View which stocks have been most impacted by Coronavirus.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insmed in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Insmed.

Insmed is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Insmed.

Insmed Incorporated (NASDAQ:INSM) announced its quarterly earnings data on Thursday, April, 30th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.02. The biopharmaceutical company earned $36.90 million during the quarter, compared to analyst estimates of $34.81 million. Insmed had a negative net margin of 162.82% and a negative return on equity of 87.35%. The business's revenue for the quarter was up 68.5% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.96) earnings per share. View Insmed's earnings history.

8 brokers have issued twelve-month target prices for Insmed's shares. Their forecasts range from $20.00 to $56.00. On average, they anticipate Insmed's share price to reach $42.00 in the next year. This suggests a possible upside of 50.2% from the stock's current price. View analysts' price targets for Insmed.

Media stories about INSM stock have been trending somewhat negative on Saturday, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Insmed earned a news impact score of -1.8 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news about Insmed.

Some companies that are related to Insmed include Horizon Therapeutics (HZNP), Ono Pharmaceutical (OPHLF), ACADIA Pharmaceuticals (ACAD), Dr.Reddy's Laboratories (RDY), Elanco Animal Health (ELAN), Ionis Pharmaceuticals (IONS), Mylan (MYL), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), PPD (SDGR), Ultragenyx Pharmaceutical (RARE), Reata Pharmaceuticals (RETA) and United Therapeutics (UTHR). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Insmed investors own include AbbVie (ABBV), Geron (GERN), Johnson & Johnson (JNJ), Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Micron Technology (MU), Opko Health (OPK) and Amarin (AMRN).

Insmed trades on the NASDAQ under the ticker symbol "INSM."

Insmed's stock is owned by a number of retail and institutional investors. Top institutional investors include Envestnet Asset Management Inc. (0.02%). Company insiders that own Insmed stock include Alfred Altomari, Donald J Hayden Jr, John Goll, Melvin Md Sharoky, Orlov S Nicole Schaeffer, Roger Adsett, Steinar J Engelsen and William Lewis. View institutional ownership trends for Insmed.

INSM stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Insmed stock in the last two years include Melvin Md Sharoky, Roger Adsett, Steinar J Engelsen, and William Lewis. View insider buying and selling activity for Insmed.

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of INSM stock can currently be purchased for approximately $27.97.

Insmed has a market capitalization of $2.83 billion and generates $136.47 million in revenue each year. The biopharmaceutical company earns $-254,340,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. Insmed employs 373 workers across the globe.

The official website for Insmed is www.insmed.com.

Insmed's mailing address is 700 US Highway 202/206, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]